Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.

Nuovi scenari nell’iperparatiroidismo secondario: etelcalcetide : Position Paper dei Nefrologi lombardi [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy] / A. Bellasi, M. Cozzolino, F. Malberti, G. Cancarini, C. Esposito, A. Genderini, C.M. Guastoni, P. Ondei, G. Pontoriero, U. Teatini, G. Vezzoli, P. Messa, F. Locatelli. - In: GIORNALE ITALIANO DI NEFROLOGIA. - ISSN 1724-5990. - 35:3(2018 May).

Nuovi scenari nell’iperparatiroidismo secondario: etelcalcetide : Position Paper dei Nefrologi lombardi [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy]

M. Cozzolino
Secondo
;
P. Messa
Penultimo
;
2018

Abstract

Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.
CKD-MBD; cinacalcet; PTH; etelcalcetide; secondary hyperparathyroidism
Settore MED/14 - Nefrologia
mag-2018
https://giornaleitalianodinefrologia.it/2018/05/09/nuovi-scenari-nelliperparatiroidismo-secondario-etelcalcetide-position-paper-dei-nefrologi-lombardi/
Article (author)
File in questo prodotto:
File Dimensione Formato  
3-Bellasi.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.95 MB
Formato Adobe PDF
1.95 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/575948
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact